Very often investors are asked to commit to the long haul when they buy into the latest new thing in the healthcare sector. With Premaitha Health the serious commercial groundwork is already underway as the diagnostics firm is ready to go to market ...
LONDON, UNITED KINGDOM--(Marketwired - Jul 4, 2014) - Premaitha Health PLC ( LSE : NIPT). Admission to AIM. Premaitha's Admission and trading of its Ordinary Shares on AIM commences at 08.00hrs today (TIDM: NIPT).
Premaitha Health PLC logo Stock analysts at Panmure Gordon raised their price objective on shares of Premaitha Health PLC (LON:NIPT) from GBX 23 ($0.35) to GBX 25 ($0.38) in a report issued on Friday. The firm currently has a �buy� rating on the stock.
Led by bullish frenzy, the shares of Premaitha Health PLC (LON:NIPT) surged 3.61% or 0.75 points in a good session. After opening the day at 21.25, the price dipped only slightly to 21 before reclaiming higher ground and hit 22.7.
Premaitha Health PLC (LON:NIPT) closed todays session on an optimistic note, gaining 1.14% or 0.25 points. Post opening the session at 21.875, the shares maintained narrow variations and hit 21.48 on the lower end and 22.4 on the upper end.
LONDON (Alliance News) - Premaitha Health PLC said Friday that it has met two key requirements for obtaining a CE Mark for its IONA in-vitro diagnostic product, for which it now expects to receive a CE Mark in February.